Clinical Trial Update: Intravesicular Abraxane for Treatment-Refractory Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results evaluate intravesical Abraxane (nab-paclitaxel) for treatment-refractory bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Sponsor: Columbia University | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-17